Silas Inman
@silasinman.bsky.social
Chief Brand Officer at MJH Life Sciences, focused on innovative, audience-driven results across OncLive, HCPLive, AJMC, Pharmacy Times, Medical Economics, and more.
Genentech’s Susvimo receives new FDA indication for diabetic retinopathy www.ophthalmologytimes.com/view/genente...
Genentech’s Susvimo receives new FDA indication for diabetic retinopathy
Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months
www.ophthalmologytimes.com
May 22, 2025 at 9:25 PM
Genentech’s Susvimo receives new FDA indication for diabetic retinopathy www.ophthalmologytimes.com/view/genente...
FDA Approves Subcutaneous Nivolumab in All Solid Tumor Indications www.cancernetwork.com/view/fda-app...
FDA Approves Subcutaneous Nivolumab in All Solid Tumor Indications
Data from CheckMate-67T support the approval of subcutaneous nivolumab in patients with solid tumors across all previously approved nivolumab indications.
www.cancernetwork.com
December 27, 2024 at 10:08 PM
FDA Approves Subcutaneous Nivolumab in All Solid Tumor Indications www.cancernetwork.com/view/fda-app...
FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity www.pharmacytimes.com/view/fda-app...
FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity
The new approval continues to expand the therapeutic potential of GLP-1 medications such as tirzepatide, now being deemed effective in patients with obstructive sleep apnea.
www.pharmacytimes.com
December 20, 2024 at 10:49 PM
FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity www.pharmacytimes.com/view/fda-app...
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer www.onclive.com/view/fda-gra...
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer
The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.
www.onclive.com
December 20, 2024 at 7:36 PM
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer www.onclive.com/view/fda-gra...
FDA Approves Remestemcel-L in Pediatric SR-aGVHD www.cancernetwork.com/view/fda-app...
FDA Approves Remestemcel-L in Pediatric SR-aGVHD
Data from the phase 3 MSB-GVHD001 trial support the FDA approval of rememstemcel-L in pediatric SR-aGVHD.
www.cancernetwork.com
December 19, 2024 at 12:15 PM
FDA Approves Remestemcel-L in Pediatric SR-aGVHD www.cancernetwork.com/view/fda-app...
FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC www.onclive.com/view/fda-app...
FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC
The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor.
www.onclive.com
December 19, 2024 at 3:53 AM
FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC www.onclive.com/view/fda-app...
Palbociclib Combo Shows Benefit to PFS in HR+, HER2+ Breast Cancer www.targetedonc.com/view/palboci... #SABCS24
Palbociclib Combo Shows Benefit to PFS in HR+, HER2+ Breast Cancer
Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic breast cancer.
www.targetedonc.com
December 12, 2024 at 10:32 PM
Palbociclib Combo Shows Benefit to PFS in HR+, HER2+ Breast Cancer www.targetedonc.com/view/palboci... #SABCS24
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer www.onclive.com/view/imlunes... #SABCS24
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
www.onclive.com
December 11, 2024 at 11:16 PM
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer www.onclive.com/view/imlunes... #SABCS24
Arlo-Cel Generates Excitement, Moves Quickly to Phase 3 Studies for Multiple Myeloma www.cgtlive.com/view/arlo-ce... #ASH24
Arlo-Cel Generates Excitement, Moves Quickly to Phase 3 Studies for Multiple Myeloma
Arlocabtagene autoleucel shows promise as a potential first in class GPRC5D-targeted CAR T-cell therapy for heavily pretreated multiple myeloma.
www.cgtlive.com
December 10, 2024 at 12:56 AM
Arlo-Cel Generates Excitement, Moves Quickly to Phase 3 Studies for Multiple Myeloma www.cgtlive.com/view/arlo-ce... #ASH24
Overflow for the overflow room resulting in some hallway session listening. I guess session 654 on myeloma was a little popular! Session started with a few great updates on isatuximab #ash24
December 9, 2024 at 7:07 PM
Overflow for the overflow room resulting in some hallway session listening. I guess session 654 on myeloma was a little popular! Session started with a few great updates on isatuximab #ash24
Innovative Hemophilia Treatments Offer Hope Amid Lingering Clinical Challenges www.hcplive.com/view/innovat... #ash24
Innovative Hemophilia Treatments Offer Hope Amid Lingering Clinical Challenges
At ASH 2024, Annette von Drygalski, MD, PharmD, described the paradigm shift that has taken place in hemophilia over the past decade.
www.hcplive.com
December 9, 2024 at 3:36 PM
Innovative Hemophilia Treatments Offer Hope Amid Lingering Clinical Challenges www.hcplive.com/view/innovat... #ash24
Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma www.onclive.com/view/daratum... #ash24
Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma
Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.
www.onclive.com
December 9, 2024 at 1:38 AM
Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma www.onclive.com/view/daratum... #ash24
Sitting in an excellent presentation by @lymphomadoc.bsky.social at another packed session on aggressive lymphomas at #ash24
December 8, 2024 at 8:28 PM
Sitting in an excellent presentation by @lymphomadoc.bsky.social at another packed session on aggressive lymphomas at #ash24
Tandem CD20/CD19 CAR Zamto-Cel Shows Promise in DLBCL www.cgtlive.com/view/tandem-... #ASH24
Tandem CD20/CD19 CAR Zamto-Cel Shows Promise in DLBCL
Zamtocabtagene autoleucel showed promising early complete response rates and survival outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma.
www.cgtlive.com
December 7, 2024 at 10:51 PM
Tandem CD20/CD19 CAR Zamto-Cel Shows Promise in DLBCL www.cgtlive.com/view/tandem-... #ASH24
Reposted by Silas Inman
Listen to my MSK colleague Eytan Stein "Revumenib Could Provide New Path to Transplant in R/R KMT2A+ Acute Leukemia" @mskcancercenter.bsky.social #leusm #ASH24 @onclive.bsky.social www.onclive.com/view/revumen...
Revumenib Could Provide New Path to Transplant in R/R KMT2A Acute Leukemia
Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib for relapsed/refractory acute leukemia with KMT2A rearrangements.
www.onclive.com
December 6, 2024 at 7:29 PM
Listen to my MSK colleague Eytan Stein "Revumenib Could Provide New Path to Transplant in R/R KMT2A+ Acute Leukemia" @mskcancercenter.bsky.social #leusm #ASH24 @onclive.bsky.social www.onclive.com/view/revumen...
Nice full session with Elias Jabbour from @mdanderson.bsky.social running through upcoming sessions at #ash24 very quickly (like only he can). Lots of great updates coming in the next few days in ALL
December 7, 2024 at 1:59 AM
Nice full session with Elias Jabbour from @mdanderson.bsky.social running through upcoming sessions at #ash24 very quickly (like only he can). Lots of great updates coming in the next few days in ALL
I have arrived at #ash24 (and on Bluesky). Excellent first talk to attend on multiple myeloma with @algarfall.bsky.social
December 6, 2024 at 8:57 PM
I have arrived at #ash24 (and on Bluesky). Excellent first talk to attend on multiple myeloma with @algarfall.bsky.social